Frontlight ResearchEarly access
Nephrotic syndrome trials in Germany
5 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
- Where
- Berlin, Dresden, Hanover
- Age
- 16 years to 75 years
- People
- 84 worldwide
- Run by
- Sanofi
See details and how to joinNCT06500702 - Phase 2Not yet taking people in GermanyA Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)
- Where
- Stuttgart
- Age
- 18 years and over
- People
- 48 worldwide
- Run by
- Medical University Innsbruck
See details and how to joinNCT07710157 - Phase 2Taking peopleStudy of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
- Where
- Cologne, Hamburg, Heidelberg
- Age
- 1 year to 17 years
- People
- 67 worldwide
- Run by
- Travere Therapeutics, Inc.
See details and how to joinNCT05003986 · EU 2023-505497-14-00 - No phaseNot yet taking people in GermanySLIT ABS: Study on Patients With Autoimmune Podocytopathy
- Where
- München
- Age
- 0 years to 99 years
- People
- 50 worldwide
- Run by
- Meyer Children's Hospital IRCCS
See details and how to joinNCT07516964 - No phaseTaking peopleThe FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)
- Where
- Aachen, Berlin, Bonn, Cologne, Dachau, Erlangen, Essen, Heidelberg, Leipzig, Marburg, Münster, Stuttgart
- People
- 500
- Run by
- Prof. Dr. Paul Brinkkoetter
See details and how to joinNCT03949972